The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors
暂无分享,去创建一个
[1] W. Scherbaum,et al. Role of the Novel mTOR Inhibitor RAD001 (Everolimus) in Anaplastic Thyroid Cancer , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[2] E. Van Obberghen,et al. Effect of Phosphoinositide-Dependent Kinase 1 on Protein Kinase B Translocation and Its Subsequent Activation , 2000, Molecular and Cellular Biology.
[3] R. Roth,et al. Akt, a Pleckstrin Homology Domain Containing Kinase, Is Activated Primarily by Phosphorylation* , 1996, The Journal of Biological Chemistry.
[4] Gaetano Rocco,et al. Activating E17K mutation in the gene encoding the protein kinase AKT in a subset of squamous cell carcinoma of the lung , 2008, Cell cycle.
[5] J A Bond,et al. Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure. , 1998, The American journal of pathology.
[6] M. Birnbaum,et al. Opposing Roles for Akt1 and Akt2 in Rac/Pak Signaling and Cell Migration* , 2006, Journal of Biological Chemistry.
[7] Se Hoon Kim,et al. Expression of down stream molecules of RET (p-ERK, p-p38 MAPK, p-JNK and p-AKT) in papillary thyroid carcinomas. , 2004, Yonsei medical journal.
[8] M. Willingham,et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[9] A. de Leiva,et al. PTEN promoter methylation in sporadic thyroid carcinomas. , 2006, Thyroid : official journal of the American Thyroid Association.
[10] M. Santoro,et al. Mutation of the PIK3CA gene in anaplastic thyroid cancer. , 2005, Cancer research.
[11] Xiang-Xi Xu,et al. Mammalian target of rapamycin is the key effector of phosphatidylinositol-3-OH-initiated proliferative signals in the thyroid follicular epithelium. , 2008, Cancer research.
[12] Marc Montminy,et al. TRB3: A tribbles Homolog That Inhibits Akt/PKB Activation by Insulin in Liver , 2003, Science.
[13] J. Jen,et al. Somatic mutations of the PTEN tumor suppressor gene in sporadic follicular thyroid tumors , 1998, Genes, chromosomes & cancer.
[14] A. Toker,et al. 3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. , 2002, Frontiers in bioscience : a journal and virtual library.
[15] A. El‐Naggar,et al. Genetic Alterations and Their Relationship in the Phosphatidylinositol 3-Kinase/Akt Pathway in Thyroid Cancer , 2007, Clinical Cancer Research.
[16] K. Takano,et al. Increased expression of phosphorylated p70S6 kinase and Akt in papillary thyroid cancer tissues. , 2003, Endocrine journal.
[17] E. Henske,et al. Tuberous sclerosis complex: linking growth and energy signaling pathways with human disease , 2005, Oncogene.
[18] Sheue-yann Cheng,et al. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[19] N. Yang,et al. Expression of Activated PIK3CA in Ovarian Surface Epithelium Results in Hyperplasia but Not Tumor Formation , 2009, PloS one.
[20] Andrea B Troxel,et al. Phase II trial of sorafenib in advanced thyroid cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] Stephanie L. Lee,et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.
[22] J. Sagartz,et al. Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. , 1996, Endocrinology.
[23] G. Mills,et al. A novel AKT3 mutation in melanoma tumours and cell lines , 2008, British Journal of Cancer.
[24] A. Toker,et al. Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT. , 2005, Molecular cell.
[25] P. Cohen,et al. Mechanism of activation of protein kinase B by insulin and IGF‐1. , 1996, The EMBO journal.
[26] Gerard M Doherty,et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2006, Thyroid : official journal of the American Thyroid Association.
[27] K. Kaestner,et al. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .
[28] G. Mills,et al. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. , 2009, Cancer research.
[29] W. K. Alfred Yung,et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers , 1997, Nature Genetics.
[30] Tak W. Mak,et al. Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis , 2006, Nature Reviews Cancer.
[31] M. Andjelkovic,et al. Activation and phosphorylation of a pleckstrin homology domain containing protein kinase (RAC-PK/PKB) promoted by serum and protein phosphatase inhibitors. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[32] C. Eng,et al. The nuclear affairs of PTEN , 2008, Journal of Cell Science.
[33] V. Vasko,et al. Akt1 contains a functional leucine-rich nuclear export sequence. , 2005, Biochemical and biophysical research communications.
[34] B. Caillou,et al. Detection of activated ras oncogenes in human thyroid carcinomas. , 1988, Oncogene.
[35] B. Hemmings,et al. Advances in protein kinase B signalling: AKTion on multiple fronts. , 2004, Trends in biochemical sciences.
[36] M. Santoro,et al. RET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture. , 2006, European journal of endocrinology.
[37] G. Chiappetta,et al. RET protein expression has no prognostic impact on the long-term outcome of papillary thyroid carcinoma. , 2001, European journal of endocrinology.
[38] J. Stock,et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.
[39] F. Khuri,et al. Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition. , 2005, Cancer research.
[40] J. Testa,et al. AKT signaling in normal and malignant cells , 2005, Oncogene.
[41] P. Vogt,et al. Oncogenic signaling of class I PI3K isoforms , 2008, Oncogene.
[42] P. Ladenson,et al. Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. , 2005, The Journal of clinical endocrinology and metabolism.
[43] F. Wyllie,et al. Activated ras oncogenes in human thyroid cancers. , 1988, Cancer research.
[44] G. Z. Cheng,et al. Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. , 2007, Cancer research.
[45] K. Ghoshal,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. , 2007, Gastroenterology.
[46] R. Weigel,et al. Identification of a human Akt3 (protein kinase B gamma) which contains the regulatory serine phosphorylation site. , 1999, Biochemical and biophysical research communications.
[47] A. Newton,et al. Akt/Protein Kinase B Is Regulated by Autophosphorylation at the Hypothetical PDK-2 Site* , 2000, The Journal of Biological Chemistry.
[48] Carlos Cordon-Cardo,et al. Pten is essential for embryonic development and tumour suppression , 1998, Nature Genetics.
[49] Caroline Kim,et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. , 2005, Endocrinology.
[50] H. Koh,et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[51] P. Edwards,et al. Integrin-linked kinase regulates phosphorylation of serine 473 of protein kinase B by an indirect mechanism , 1999, Oncogene.
[52] B. Evers,et al. Activation of PPARγ increases PTEN expression in pancreatic cancer cells , 2003 .
[53] D. Powell,et al. The RET/PTC3 oncogene: metastatic solid-type papillary carcinomas in murine thyroids. , 1998, Cancer research.
[54] J. Dumont,et al. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. , 2000, The Biochemical journal.
[55] H. Northrup,et al. Tuberous sclerosis complex: disease modifiers and treatments. , 2008, Current opinion in pediatrics.
[56] N. Eberhardt,et al. The Paired Box-8/Peroxisome Proliferator-Activated Receptor-γ Oncogene in Thyroid Tumorigenesis , 2007 .
[57] B. Hemmings,et al. Molecular cloning and identification of a serine/threonine protein kinase of the second-messenger subfamily. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[58] M. Birnbaum,et al. Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.
[59] M. Willingham,et al. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. , 2002, Thyroid : official journal of the American Thyroid Association.
[60] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[61] B. Weintraub,et al. Interaction of human beta 1 thyroid hormone receptor and its mutants with DNA and retinoid X receptor beta. T3 response element-dependent dominant negative potency. , 1993, The Journal of clinical investigation.
[62] P. Vogt,et al. Cancer-specific mutations in phosphatidylinositol 3-kinase. , 2007, Trends in biochemical sciences.
[63] Frank McCormick,et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.
[64] Y. Pekarsky,et al. The role of TCL1 in human T-cell leukemia , 2001, Oncogene.
[65] E. Fridman,et al. AKT1 E17 K pleckstrin homology domain mutation in urothelial carcinoma. , 2009, Cancer genetics and cytogenetics.
[66] M. Saji,et al. Overexpression and overactivation of Akt in thyroid carcinoma. , 2001, Cancer research.
[67] M. Santoro,et al. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas , 1990, Cell.
[68] B. Spiegelman,et al. PAX8-PPARγ1 Fusion in Oncogene Human Thyroid Carcinoma , 2000 .
[69] L. Bastholt,et al. Motesanib diphosphate in progressive differentiated thyroid cancer. , 2008, The New England journal of medicine.
[70] M. Benezra,et al. BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. , 2008, The Journal of clinical endocrinology and metabolism.
[71] B. Evers,et al. Increased incidence of well-differentiated thyroid cancer associated with Hashimoto thyroiditis and the role of the PI3k/Akt pathway. , 2007, Journal of the American College of Surgeons.
[72] M. Willingham,et al. Inhibition of phosphatidylinositol 3-kinase delays tumor progression and blocks metastatic spread in a mouse model of thyroid cancer. , 2007, Carcinogenesis.
[73] G. Chiappetta,et al. RET activation and clinicopathologic features in poorly differentiated thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[74] M. Willingham,et al. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer , 2009, Oncogene.
[75] T. Giordano,et al. Paired box gene 8-peroxisome proliferator-activated receptor-gamma fusion protein and loss of phosphatase and tensin homolog synergistically cause thyroid hyperplasia in transgenic mice. , 2009, Endocrinology.
[76] David M Sabatini,et al. Defining the role of mTOR in cancer. , 2007, Cancer cell.
[77] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.
[78] R. Abraham,et al. The Mammalian Target of Rapamycin Signaling Pathway: Twists and Turns in the Road to Cancer Therapy , 2007, Clinical Cancer Research.
[79] M. McMahon,et al. Oncogenic transformation of cells by a conditionally active form of the protein kinase Akt/PKB. , 2000, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[80] G. Stamp,et al. Binding of Ras to Phosphoinositide 3-Kinase p110α Is Required for Ras- Driven Tumorigenesis in Mice , 2007, Cell.
[81] Peter Kraft,et al. PIK3CA mutation is associated with poor prognosis among patients with curatively resected colon cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[82] Yuri E Nikiforov,et al. Thyroid carcinoma: molecular pathways and therapeutic targets , 2008, Modern Pathology.
[83] C. Cordon-Cardo,et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[84] T. Haruta,et al. Mammalian Target of Rapamycin Pathway Regulates Insulin Signaling via Subcellular Redistribution of Insulin Receptor Substrate 1 and Integrates Nutritional Signals and Metabolic Signals of Insulin , 2001, Molecular and Cellular Biology.
[85] Y. Gotoh,et al. Scaffolding function of PAK in the PDK1–Akt pathway , 2008, Nature Cell Biology.
[86] Wei Wang,et al. High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. , 2007, The Journal of clinical endocrinology and metabolism.
[87] A. Di Cristofano,et al. Pten loss in the mouse thyroid causes goiter and follicular adenomas: insights into thyroid function and Cowden disease pathogenesis. , 2007, Cancer research.
[88] G. Chiappetta,et al. Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. , 1996, Oncogene.
[89] I. Campbell,et al. The phosphatidylinositol 3'-kinase p85alpha gene is an oncogene in human ovarian and colon tumors. , 2001, Cancer research.
[90] M. Saji,et al. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. , 2001, Thyroid : official journal of the American Thyroid Association.
[91] Jason A. Koutcher,et al. Identification of a tumour suppressor network opposing nuclear Akt function , 2006, Nature.
[92] Ji Luo,et al. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism , 2006, Nature Reviews Genetics.
[93] Hong Liu,et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[94] Jing Li,et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome , 1997, Nature Genetics.
[95] D. Stokoe. The phosphoinositide 3-kinase pathway and cancer , 2005, Expert Reviews in Molecular Medicine.
[96] P. Hou,et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. , 2008, The Journal of clinical endocrinology and metabolism.
[97] T. Roberts,et al. Should individual PI3 kinase isoforms be targeted in cancer? , 2009, Current opinion in cell biology.
[98] A. Grossman,et al. Are neuroendocrine tumours a feature of tuberous sclerosis? A systematic review. , 2008, Endocrine-related cancer.
[99] B. Park,et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways , 2009, Proceedings of the National Academy of Sciences.
[100] Robert D Cardiff,et al. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.
[101] J. Gutkind,et al. A Novel Role for Phosphatidylinositol 3-Kinase β in Signaling from G Protein-coupled Receptors to Akt* , 2000, The Journal of Biological Chemistry.
[102] G. Viglietto,et al. PTEN expression is reduced in a subset of sporadic thyroid carcinomas: evidence that PTEN-growth suppressing activity in thyroid cancer cells is mediated by p27kip1 , 2000, Oncogene.
[103] A. Bilancio,et al. Signalling by PI3K isoforms: insights from gene-targeted mice. , 2005, Trends in biochemical sciences.
[104] M. Wigler,et al. PTEN, a Putative Protein Tyrosine Phosphatase Gene Mutated in Human Brain, Breast, and Prostate Cancer , 1997, Science.
[105] J. Yeh,et al. Differential nuclear and cytoplasmic expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors. , 2000, The American journal of pathology.
[106] M. Pierotti,et al. TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. , 1992, Oncogene.
[107] M. Santoro,et al. Conditional expression of RET/PTC induces a weak oncogenic drive in thyroid PCCL3 cells and inhibits thyrotropin action at multiple levels. , 2003, Molecular endocrinology.
[108] P. Cohen,et al. Role of Translocation in the Activation and Function of Protein Kinase B* , 1997, The Journal of Biological Chemistry.
[109] A. El‐Naggar,et al. Phosphatidylinositol 3-kinase/akt and ras/raf-mitogen-activated protein kinase pathway mutations in anaplastic thyroid cancer. , 2008, The Journal of clinical endocrinology and metabolism.
[110] T. Tsuruo,et al. Modulation of Akt kinase activity by binding to Hsp90. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[111] Huiling He,et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion , 2007, Proceedings of the National Academy of Sciences.
[112] A. Di Cristofano,et al. Oncogenic Kras requires simultaneous PI3K signaling to induce ERK activation and transform thyroid epithelial cells in vivo. , 2009, Cancer research.
[113] S. Asa,et al. Pathogenetic mechanisms in thyroid follicular-cell neoplasia , 2006, Nature Reviews Cancer.
[114] B. Hemmings,et al. Identification of a PKB/Akt Hydrophobic Motif Ser-473 Kinase as DNA-dependent Protein Kinase*♦ , 2004, Journal of Biological Chemistry.
[115] P. Vogt,et al. Oncogenic transformation induced by membrane-targeted Akt2 and Akt3 , 2001, Oncogene.
[116] S. Sherman. Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. , 2009, The Journal of clinical endocrinology and metabolism.
[117] Carmen Blanco-Aparicio,et al. PTEN, more than the AKT pathway. , 2007, Carcinogenesis.
[118] M. Ringel,et al. Dysregulation of the phosphatidylinositol 3-kinase pathway in thyroid neoplasia. , 2008, Endocrinology and metabolism clinics of North America.
[119] V. Vasko,et al. Chronic expression of RET/PTC 3 enhances basal and insulin‐stimulated PI3 kinase/AKT signaling and increases IRS‐2 expression in FRTL‐5 thyroid cells , 2004, Molecular carcinogenesis.
[120] Hong Wang,et al. Akt-mediated phosphorylation and activation of estrogen receptor alpha is required for endometrial neoplastic transformation in Pten+/- mice. , 2006, Cancer research.
[121] G. Viglietto,et al. Complex regulation of the cyclin-dependent kinase inhibitor p27kip1 in thyroid cancer cells by the PI3K/AKT pathway: regulation of p27kip1 expression and localization. , 2005, The American journal of pathology.
[122] S. Staal. Molecular cloning of the akt oncogene and its human homologues AKT1 and AKT2: amplification of AKT1 in a primary human gastric adenocarcinoma. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[123] Brian A. Hemmings,et al. Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.
[124] W. Liu,et al. Up-regulation of Akt3 in Estrogen Receptor-deficient Breast Cancers and Androgen-independent Prostate Cancer Lines* , 1999, The Journal of Biological Chemistry.
[125] Brian A. Hemmings,et al. Carboxyl-Terminal Modulator Protein (CTMP), a Negative Regulator of PKB/Akt and v-Akt at the Plasma Membrane , 2001, Science.
[126] D. Rawlings,et al. Protein Kinase C βII Regulates Akt Phosphorylation on Ser-473 in a Cell Type- and Stimulus-specific Fashion*♦ , 2004, Journal of Biological Chemistry.
[127] S. Baker,et al. PTEN and the PI3-kinase pathway in cancer. , 2009, Annual review of pathology.
[128] Satoshi Matsumoto,et al. Frequent somatic mutations in PTEN and TP53 are mutually exclusive in the stroma of breast carcinomas , 2002, Nature Genetics.
[129] J. Wesselink,et al. Molecular cloning, expression and characterization of the human serine/threonine kinase Akt-3. , 1999, European journal of biochemistry.
[130] M. Sughayer,et al. The transforming mutation E17K/AKT1 is not a major event in B-cell-derived lymphoid leukaemias , 2008, British Journal of Cancer.
[131] P. Hou,et al. Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3‐kinase/AKT signaling pathway in thyroid tumors , 2008, Cancer.
[132] Erica A Golemis,et al. Identification of a chromosome 3p14.3-21.1 gene, APPL, encoding an adaptor molecule that interacts with the oncoprotein-serine/threonine kinase AKT2 , 1999, Oncogene.
[133] M. Saji,et al. AKT in thyroid tumorigenesis and progression. , 2007, Endocrinology.
[134] M. Hall,et al. TOR Signaling in Growth and Metabolism , 2006, Cell.
[135] Michael C. Ostrowski,et al. Genomic alterations in tumor stroma. , 2009, Cancer research.
[136] Spyro Mousses,et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer , 2007, Nature.
[137] J. Meinkoth,et al. Ras signaling through PI3K confers hormone-independent proliferation that is compatible with differentiation , 2000, Oncogene.
[138] J. Brugge,et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.
[139] M. Ladanyi,et al. Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. , 2009, Cancer research.
[140] Pier Paolo Pandolfi,et al. The Multiple Roles of PTEN in Tumor Suppression , 2000, Cell.
[141] N. Masuyama,et al. Akt mediates Rac/Cdc42-regulated cell motility in growth factor-stimulated cells and in invasive PTEN knockout cells , 2001, Current Biology.
[142] P. Vogt,et al. Cancer-specific mutations in PIK3CA are oncogenic in vivo , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[143] M. Pierotti,et al. Overexpression of the C-MET/HGF receptor in human thyroid carcinomas derived from the follicular epithelium , 1995, Journal of endocrinological investigation.
[144] B. Nelkin,et al. Dual inhibition of mitogen-activated protein kinase kinase and mammalian target of rapamycin in differentiated and anaplastic thyroid cancer. , 2009, The Journal of clinical endocrinology and metabolism.
[145] J. Qin,et al. SIN1/MIP1 Maintains rictor-mTOR Complex Integrity and Regulates Akt Phosphorylation and Substrate Specificity , 2006, Cell.
[146] Jiachao Liang,et al. Phase II trial of sorafenib in metastatic thyroid cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] Charis Eng,et al. Silencing of the PTEN tumor‐suppressor gene in anaplastic thyroid cancer , 2002, Genes, chromosomes & cancer.
[148] C. J. Chen,et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected]. , 2000, Science.
[149] A. Toker,et al. Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer. , 2009, Cellular signalling.
[150] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[151] W. Sellers,et al. Drug discovery approaches targeting the PI3K/Akt pathway in cancer , 2008, Oncogene.
[152] V. Vasko,et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer , 2004, Journal of Medical Genetics.
[153] David Sidransky,et al. Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. , 2007, The Journal of clinical endocrinology and metabolism.
[154] Wenjun Guo,et al. The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem Cells , 2008, Cell.
[155] A. Newton,et al. PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. , 2005, Molecular cell.
[156] Metin N. Gurcan,et al. Pten in Stromal Fibroblasts Suppresses Mammary Epithelial Tumors , 2009, Nature.
[157] C. Larsson,et al. Somatic deletions and mutations in the Cowden disease gene, PTEN, in sporadic thyroid tumors. , 1997, Cancer research.
[158] H. Koh,et al. Inhibition of Akt and Its Anti-apoptotic Activities by Tumor Necrosis Factor-induced Protein Kinase C-related Kinase 2 (PRK2) Cleavage* , 2000, The Journal of Biological Chemistry.
[159] E. Vokes,et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[160] Ralph Weissleder,et al. Effective Use of PI3K and MEK Inhibitors to Treat Mutant K-Ras G12D and PIK3CA H1047R Murine Lung Cancers , 2008, Nature Medicine.